（记者 曾健辉） 每经头条（nbdtoutiao）——独家对话特斯拉FSD跨美第一人：4400公里"零接管"，手没碰过方向盘！作 为激光雷达销售员，他为何站队马斯克的"纯视觉"？ 每经AI快讯，普洛药业1月9日晚间发布公告称，截至2026年1月8日，本次回购方案已实施完毕。公司 实际回购时间区间为2025年11月28日至2026年1月8日，公司通过股票回购专用证券账户以集中竞价交易 方式累计回购公司股份2209万股，占公司目前总股本的1.91%，最高成交价16.85元/股，最低成交价 15.71元/股，成交总金额为人民币约3.6亿元回购资金总额为人民币约3.6亿元。 ...

Core Viewpoint - Pro Pharmaceutical (000739) has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development and custom manufacturing projects (CDMO) [1] Group 1: Strategic Cooperation - The agreement establishes a strategic partnership between Pro Pharmaceutical and Xi'an New Tong, focusing on long-term collaboration in CDMO projects [1] - This collaboration is expected to enhance Pro Pharmaceutical's CDMO business competitiveness and facilitate its expansion in this sector [1] Group 2: Xi'an New Tong's IPO - Xi'an New Tong is currently preparing for an IPO on the Sci-Tech Innovation Board, with its application accepted on December 29, 2025, aiming to raise 900 million yuan [1]

Core Viewpoint - Pro Pharmaceutical (000739.SZ) has signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development as well as custom manufacturing projects [2] Group 1 - The agreement does not involve substantial transactions and will not have a significant impact on the company's operating performance for the current year [2] - The future impact on the company's operating performance will depend on subsequent specific project agreements and their implementation [2]

Core Viewpoint - Pro Pharmaceutical (000739.SZ) has signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development and custom manufacturing projects (CDMO projects) [1] Group 1 - The agreement is based on principles of equality, mutual benefit, and complementary advantages [1]

智通财经APP讯，普洛药业(000739.SZ)公告，公司作为乙方与西安新通药物研究股份有限公司(简称"西 安新通"、甲方)近日签订了《战略合作框架协议》，旨在开展创新药研发与外包定制生产项目("CDMO 项目")的长期合作。 ...

Core Viewpoint - The company has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to collaborate in the fields of innovative drug research and development and contract development and manufacturing organization (CDMO) projects for a duration of ten years [1] Group 1: Agreement Details - The agreement aims to enhance the company's competitiveness in the CDMO business through complementary advantages [1] - This framework agreement does not involve specific transactions and will not have a significant impact on the company's operating performance for the current year [1] - The impact on future operating performance will depend on the signing and implementation of specific project agreements [1] Group 2: Intellectual Property and Responsibilities - During the collaboration, research results and related intellectual property will belong to Xi'an New Tong [1] - The company commits to using the relevant technologies and processes only within the scope of the cooperation and guarantees that the development results do not infringe on third-party rights [1] Group 3: Risks and Uncertainties - The specific cooperation matters will require separate agreements, and there is uncertainty regarding the ability to achieve substantial cooperation [1] - The progress of the collaboration may be affected by industry policies, market conditions, and other force majeure factors [1]

Core Viewpoint - The company, Pro Pharmaceutical (000739), has signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development and custom manufacturing projects (CDMO projects) [1] Group 1 - The collaboration aims to expand the company's CDMO business and enhance its competitiveness in the CDMO sector [1]

证券代码：000739 证券简称：普洛药业 公告编号：2026-02 1.本次公司与合作方签署的《战略合作框架协议》，本着平等互利、优 势互补的原则，经友好协商，就研发与外包定制生产项目的合作关系达成共 识。具体项目合作事宜将由双方另行签署具体协议。 2.本次签署的《战略合作框架协议》对公司本年度经营业绩不会构成 重大影响，对公司未来年度经营业绩的影响将视公司与合作方后续签订的 具体项目协议以及实施情况而确定。 3.公司不存在最近三年披露的框架协议无进展或进展未达预期的情况。 一、战略框架协议签署概况 普洛药业股份有限公司(以下简称"公司"或"乙方")与西安新通药 物研究股份有限公司（以下简称"西安新通"或"甲方"）本着平等互利、 优势互补的原则，于近日签订了《战略合作框架协议》，旨在开展创新药 研发与外包定制生产项目（以下简称"CDMO项目"）的长期合作。 二、战略合作框架协议合作方基本情况 普洛药业股份有限公司 关于签署战略合作框架协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本次签署的《战略合作框架协议》仅为框架性协议，不涉及实质性交 易， ...

Core Viewpoint - The company has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development as well as outsourced custom manufacturing projects [1] Group 1: Agreement Details - The agreement is a framework agreement and does not involve substantial transactions or constitute a major asset restructuring [1] - The collaboration is expected to benefit the company's CDMO (Contract Development and Manufacturing Organization) business expansion and enhance its competitive edge [1] Group 2: Financial Impact - The agreement is not expected to have a significant impact on the company's operating performance for the current fiscal year [1] - Future performance implications will depend on subsequent specific project agreements and their implementation [1]

格隆汇1月5日丨普洛药业(000739.SZ)公布，截至2025年12月31日，公司通过回购专用证券账户以集中 竞价方式回购公司股份20,370,000股，占公司目前总股本的1.76%，最高成交价为16.85元/股，最低成交 价为15.71元/股，成交总金额为332,025,552.50元（不含交易费用）。本次回购符合公司回购股份方案及 相关法律法规的要求。 ...